NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug

Benzinga_recent_news01:35

Ketamine is a dissociative anesthetic that has some hallucinogenic effects. It is primarily used in medical and veterinary settings for surgery and pain management, and increasingly for mental health ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620749845?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/Agitated-Depression-Mentioned.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-17 01:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620749845","market":"hk","top_or_hot":-1,"title":"NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug","media":"Benzinga_recent_news","content":"<div>\n<p>Ketamine is a dissociative anesthetic that has some hallucinogenic effects. It is primarily used in medical and veterinary settings for surgery and pain management, and increasingly for mental health ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 01:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ketamine is a dissociative anesthetic that has some hallucinogenic effects. It is primarily used in medical and veterinary settings for surgery and pain management, and increasingly for mental health ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug","article_id":"2620749845","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/Agitated-Depression-Mentioned.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620749845","pubTimestamp":1773682500,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4217":"自存仓储房地产信托","SMA":"Smartstop Self Storage REIT Inc"},"translate_title":"FDA发出氯胺酮抑郁症药物NDA信号后，NRx Pharma股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"SMA":1},"content_text":"Ketamine is a dissociative anesthetic that has some hallucinogenic effects. It is primarily used in medical and veterinary settings for surgery and pain management, and increasingly for mental health treatment.\nThe FDA has confirmed its willingness to review NRx’s application for New Drug Approval of NRX-100, based on substantial evidence of effectiveness derived from existing trials.\nNotably, the agency did not request additional clinical trials, and the company plans to submit existing patient-level data for review, which could expedite the approval process.\nThe company intends to submit its New Drug Application for NRX-100 by June 2026.\nAdditionally, NRX-100 has shown dramatic superiority to placebo treatments and non-inferiority compared to electroshock therapy in trials, with significant reductions in suicidal ideation.\nKetamine has demonstrated a statistically significant reduction in suicidal ideation. Electroshock therapy, the only currently-approved treatment for suicidal ideation, demonstrated a 30% incidence of memory loss, whereas ketamine did not.\nThis positions NRx Pharmaceuticals to potentially address a critical market need, as over 16 million Americans experience depression annually, with 3.6 million contemplating suicide.\nCurrently, NRXP is trading 14.8% above its 20-day simple moving average (SMA) and 3.3% above its 50-day SMA, indicating short-term strength. However, it remains 8.2% below its 100-day SMA and 20.7% below its 200-day SMA, suggesting some challenges in maintaining longer-term momentum.\nThe stock has increased by 1.86% over the past 12 months and is currently positioned closer to its 52-week highs than lows, reflecting a relatively stable performance in a volatile market.\nThe RSI is at 48.03, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at -0.0520, with the signal line at -0.0693, suggesting a bullish crossover as the MACD is above the signal line.\nThe combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while there is potential for upward movement, caution is warranted.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating. Recent analyst moves include:\nNRXP Price Action: NRx Pharmaceuticals shares were up 11.70% at $2.07 at the time of publication on Monday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620749845","isCrawlerRequest":true}